Update on heart failure management and future directions.
- Author:
Hong Mi CHOI
1
;
Myung Soo PARK
;
Jong Chan YOUN
Author Information
- Publication Type:Review
- Keywords: Heart failure; Diagnosis; Management; Prognosis
- MeSH: Biomarkers; Cardiovascular Diseases; Diagnosis; Genetic Testing; Health Care Costs; Heart Failure*; Heart Transplantation; Heart*; Heart-Assist Devices; Humans; Korea; Mortality; Prevalence; Prognosis
- From:The Korean Journal of Internal Medicine 2019;34(1):11-43
- CountryRepublic of Korea
- Language:English
- Abstract: Heart failure (HF) is an important cardiovascular disease because of its increasing prevalence, significant morbidity, high mortality, and rapidly expanding health care cost. The number of HF patients is increasing worldwide, and Korea is no exception. There have been marked advances in definition, diagnostic modalities, and treatment of HF over the past four decades. There is continuing effort to improve risk stratification of HF using biomarkers, imaging and genetic testing. Newly developed medications and devices for HF have been widely adopted in clinical practice. Furthermore, definitive treatment for end-stage heart failure including left ventricular assist device and heart transplantation are rapidly evolving as well. This review summarizes the current state-of-the-art management for HF and the emerging diagnostic and therapeutic modalities to improve the outcome of HF patients.
